Nouryant Again Denied Marketing Approval in Europe

Nouryant Again Denied Marketing Approval in Europe

312047

Nouryant Again Denied Marketing Approval in Europe

A committee of the European Medicines Agency (EMA) has issued a negative opinion for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as an add-on medication for treating “off” episodes in those with Parkinson’s disease in the European Union. The Committee for Medicinal Products for Human Use (CHMP) is maintaining its initial assessment, the therapy’s developer, Kyowa Kirin, announced in a press release. “We are disappointed by the CHMP opinion. We will take time to assess our plans for…

You must be logged in to read/download the full post.